Frontiers in Human Neuroscience
2018
Vladimir Bostanov, Lilian Ohlrogge, Rita Britz et al.
Mindfulness-based interventions have proved effective in reducing various clinical symptoms and in improving general mental health and well-being. The investigation of the mechanisms of therapeutic change needs methods for assessment of mindfulness. Existing self-report measures have, however, been strongly criticized on various grounds, including distortion of the original concept, response...
Frontiers in Psychology
2018
Ragni B Haukaas, Ingrid B Gjerde, Grunde Varting et al.
The Attention Training Technique (ATT) and Mindful Self-Compassion (MSC) are two promising psychological interventions. ATT is a 12-min auditory exercise designed to strengthen attentional control and promote external focus of attention, while MSC uses guided meditation and exercises designed to promote self-compassion. In this randomized controlled trial (RCT), a three-session intervention...
Journal of Affective Disorders
January 1, 2018
Mu-Hong Chen, Cheng-Ta Li, Wei-Chen Lin et al.
A single low-dose ketamine infusion exhibited a rapid antidepressant effect within 1h. Despite its short biological half-life (approximately 3h), the antidepressant effect of ketamine has been demonstrated to persist for several days. However, changes in brain function responsible for the persistent antidepressant effect of a single low-dose ketamine infusion remain unclear METHODS: Twenty-four...
The Journal of Clinical Psychiatry
2018
Chittaranjan Andrade
A growing body of literature suggests that ketamine, administered in subanesthetic doses, has early-onset antidepressant action in patients with severe and even treatment-refractory depression. Many case reports, open-label studies, and randomized controlled trials (RCTs) suggest that ketamine may have dramatic antisuicidal effects, as well. This article examines the benefits of ketamine in...
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion
2018
Rodrigo Pérez-Esparza
Current alternatives for the treatment of major depressive disorder lack efficacy and have a delayed onset of action. Recently, the glutamatergic neurotransmission system has been noted to play an important role in the pathophysiology of this disorder. Ever since the first report of the antidepressant effects of the N-methyl-D-aspartate receptor antagonist, ketamine, research has been...
The Journal of Clinical Psychiatry
2018
Christina Sophia Albott, Kelvin O Lim, Miriam K Forbes et al.
The present study examined the efficacy, safety, and durability of repeated ketamine infusions for the treatment of comorbid posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) in a sample of veterans. Individuals with comorbid DSM-5-defined PTSD and DSM-IV-defined major depressive disorder (N = 15) received 6 intravenous ketamine infusions (0.5 mg/kg) on a...
NeuroImage: Clinical
2018
Jessica L Reed, Allison C. Nugent, Maura L. Furey et al.
An urgent need exists for faster-acting pharmacological treatments in major depressive disorder (MDD). The glutamatergic modulator ketamine has been shown to have rapid antidepressant effects, but much remains unknown about its mechanism of action. Functional MRI (fMRI) can be used to investigate how ketamine impacts brain activity during cognitive and emotional processing. This double-blind,...
Case reports in anesthesiology
2018
Garret Weber, JuHan Yao, Shemeica Binns et al.
Chronic neuropathic pain and depression are often comorbid. Ketamine has been used to treat refractory pain. There is emerging evidence for use in depression. We present a case of a pediatric patient who was successfully treated with subanesthetic intravenous ketamine infusion for chronic neuropathic pain and suicidality.
Frontiers in Neural Circuits
2018
Tony Ye, Mitchell J Bartlett, Matthew B Schmit et al.
Introduction: Treatment-resistant depression, post-traumatic stress disorder, chronic pain, and L-DOPA-induced dyskinesia in Parkinson's disease are characterized by hypersynchronous neural oscillations. Sub-anesthetic ketamine is effective at treating these conditions, and this may relate to ketamine's capacity to reorganize oscillatory activity throughout the brain. For example, a single...
Caspian journal of internal medicine
2018
Farzan Kheirkhah, Gooya Tayyebi, Seyed Mozaffar Rabiee et al.
Major depressive disorder is a severe, heterogeneous, common medical illness and a leading cause of disability throughout the world that poses a significant public health issue. Previous studies have shown rapid antidepressant effects following a single administration of ketamine. This study aimed to assess the impact of route of administration and dose of ketamine for the reduction of...
Frontiers in Synaptic Neuroscience
2018
Ryan D Shepard, Ludovic D Langlois, Caroline A Browne et al.
Mounting evidence suggests that the long-term effects of adverse early life stressors on vulnerability to drug addiction and mood disorders are related to dysfunction of brain monoaminergic signaling in reward circuits. Recently, there has been a growing interest in the lateral habenula (LHb) as LHb dysfunction is linked to the development of mental health disorders through monoaminergic...
Frontiers in Molecular Neuroscience
2018
Christina T LaGamma, William W Tang, Ashlea A Morgan et al.
Ketamine has been found to have rapid, long-lasting antidepressant effects in treatment-resistant (TR) patients with major depressive disorder (MDD). Recently, we have also shown that ketamine acts as a prophylactic to protect against the development of stress-induced depressive-like behavior in mice, indicating that a preventative treatment against mental illness using ketamine is possible....
Journal of experimental neuroscience
2018
Shigeyuki Chaki, Jun-Ichi Yamaguchi
Historically, identification of active metabolites has contributed to drug discovery for psychiatric disorders. It has led to the identification of new medications such as desipramine (a metabolite of imipramine) and paliperidone (a metabolite of risperidone). (R,S)-Ketamine, which has been regarded as the greatest breakthrough in depression research, is rapidly and stereoselectively...
Frontiers in Molecular Neuroscience
2018
Bartłomiej Pochwat, Bernadeta Szewczyk, Katarzyna Kotarska et al.
N-methyl-D-aspartate receptor (NMDAR) modulators induce rapid and sustained antidepressant like-activity in rodents through a molecular mechanism of action that involves the activation of Ca2+ dependent signaling pathways. Moreover, ketamine, a global NMDAR antagonist is a potent, novel, and atypical drug that has been successfully used to treat major depressive disorder (MDD). However, because...
Cold Spring Harbor Symposia on Quantitative Biology
2018
Yihui Cui, Yan Yang, Yiyan Dong et al.
preprint
The rapid antidepressant effect of ketamine is arguably one of the most significant advances in the mental health field in the last half century. However, its mechanism of action has remained elusive. Here, we describe our latest discovery on how ketamine blocks N-methyl-D-aspartate receptor (NMDAR)-dependent burst firing of an "antireward" center in the brain, the lateral habenula (LHb), to...
Journal of Drug and Alcohol Research
2018
Bruk Getachew, Yousef Tizabi
17 citations
The co-morbidity between heavy drinking and depression can negatively influence successful cessation of alcohol use. Since ketamine, a glutamatergic NMDA receptor antagonist, has shown promise as a quick-acting antidepressant, we studied its effects specifically on alcohol withdrawal-induced depression. We also evaluated the effects of NBQX an AMPA/kainate receptor antagonist, because some of...
Brazilian Journal of Psychiatry
2018
Ivan Y. Barenboim, Beny Lafer
8 citations
DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
Frontiers in Human Neuroscience
2018
Kamila Osypiuk, Evan Thompson, Peter M. Wayne
Dynamic and static body postures are a defining characteristic of mind-body practices such as Tai Chi and Qigong (TCQ). A growing body of evidence supports the hypothesis that TCQ may be beneficial for psychological health, including management and prevention of depression and anxiety. Although a variety of causal factors have been identified as potential mediators of such health benefits,...
Restorative Neurology and Neuroscience
2018
Madhuri R Tolahunase, Rajesh Sagar, Muneeb Faiq et al.
Current interventions for major depressive disorder (MDD) are suboptimal, and only one third respond to them on initial treatment. Neuroplasticity theories are the basis for several emerging treatments. Evidence on the impact of yoga, a well-known mind-body intervention, on neuroplasticity in MDD is limited. To determine the effects of 12-week yoga- and meditation-based lifestyle intervention...
Journal of Evidence-Based Integrative Medicine
2018
Gary Groesbeck, Donna Bach, Peta Stapleton et al.
This study investigated changes in psychological and physiological markers during a weekend meditation workshop (N = 34). Psychological symptoms of anxiety, depression, posttraumatic stress disorder (PTSD) and happiness were assessed. Physiological markers included cortisol, salivary immunoglobulin A (SigA), heart rate variability (HRV), blood pressure (BP), and resting heart rate (RHR). On...